2017年3月3-4日，中国临床肿瘤学会（Chinese Society of Clinical Oncology，CSCO）和中国抗癌协会肺癌专业委员会联合主办了第十四届“中国肺癌高峰论坛”。本次论坛的主题是“精准与联合：共谱免疫治疗新乐章”。检查点抑制剂（Check...2017年3月3-4日，中国临床肿瘤学会（Chinese Society of Clinical Oncology，CSCO）和中国抗癌协会肺癌专业委员会联合主办了第十四届“中国肺癌高峰论坛”。本次论坛的主题是“精准与联合：共谱免疫治疗新乐章”。检查点抑制剂（Checkpoint inhibitor）因其对多肿瘤类别广泛的适用性及能带来持久的有效缓解，短期内在全球范围掀起了免疫治疗的狂潮。而在非小细胞肺癌患者中，免疫治疗同样带来了令人欣喜的临床获益。展开更多
Background The efficacy of pemetrexed in the second-line treatment of Chinese patients with advanced non-small cell lung cancer （NSCLC） has been shown to be similar to that of docetaxel in a recent study; additional...Background The efficacy of pemetrexed in the second-line treatment of Chinese patients with advanced non-small cell lung cancer （NSCLC） has been shown to be similar to that of docetaxel in a recent study; additionally, pemetrexed was associated with much better safety and toxicity profiles. Here, the survival without common toxicity criteria grade 3/4 toxicity （SWT） data from a post hoc analysis of this recent prospective NSCLC study in Chinese patients is reported. This post hoc analysis differs from the main study; it focuses on the nonsquamous population to align with the current approval for pemetrexed in China. Methods A total of 154 patients with nonsquamous NSCLC received either pemetrexed （500 mg/m2 intravenously （IV）） or docetaxel （75 mg/m2 IV） on day 1 of 21-day cycles. SWT was analyzed using Kaplan-Meier and univariate Cox methods. Results Patients treated with pemetrexed had a longer median SWT than patients treated with docetaxel （7.4 months versus 1.2 months; unadjusted hazard ratio =0.59, 95% confidence interval CCI}： 0.41-0.84; P=0.003）. At 12 and 18months, the SWT event-free probability for pemetrexed patients （18 months： 24.5%, 95%C/ 13.9%-36.6%, vs. 12.3%, 95% CI 4.8%-23.6%） was greater than that for docexatel patients （12 months： 37.3%, 95% CI 26.5%- 48.0%, vs. 23.3%, 95% CI 14.4-33.4）. The progression- free survival without common toxicity criteria grade 3/4 toxicity （PFS-WT） was also statistically significantly longer for patients treated with pemetrexed than patients treated with docetaxel （1.9 months vs. 1.1 months, P=0.002）. Conclusions Chinese patients with nonsquamous NSCLC disease treated with pemetrexed had improved SWT beyond 6 months than those receiving docetaxel. This analysis supports a benefit-to-risk profile that favors pemetrexed over docetaxel in the second-line treatment of Chinese nonsquamous NSCLC patients.展开更多
文摘2017年3月3-4日，中国临床肿瘤学会（Chinese Society of Clinical Oncology，CSCO）和中国抗癌协会肺癌专业委员会联合主办了第十四届“中国肺癌高峰论坛”。本次论坛的主题是“精准与联合：共谱免疫治疗新乐章”。检查点抑制剂（Checkpoint inhibitor）因其对多肿瘤类别广泛的适用性及能带来持久的有效缓解，短期内在全球范围掀起了免疫治疗的狂潮。而在非小细胞肺癌患者中，免疫治疗同样带来了令人欣喜的临床获益。
文摘Background The efficacy of pemetrexed in the second-line treatment of Chinese patients with advanced non-small cell lung cancer （NSCLC） has been shown to be similar to that of docetaxel in a recent study; additionally, pemetrexed was associated with much better safety and toxicity profiles. Here, the survival without common toxicity criteria grade 3/4 toxicity （SWT） data from a post hoc analysis of this recent prospective NSCLC study in Chinese patients is reported. This post hoc analysis differs from the main study; it focuses on the nonsquamous population to align with the current approval for pemetrexed in China. Methods A total of 154 patients with nonsquamous NSCLC received either pemetrexed （500 mg/m2 intravenously （IV）） or docetaxel （75 mg/m2 IV） on day 1 of 21-day cycles. SWT was analyzed using Kaplan-Meier and univariate Cox methods. Results Patients treated with pemetrexed had a longer median SWT than patients treated with docetaxel （7.4 months versus 1.2 months; unadjusted hazard ratio =0.59, 95% confidence interval CCI}： 0.41-0.84; P=0.003）. At 12 and 18months, the SWT event-free probability for pemetrexed patients （18 months： 24.5%, 95%C/ 13.9%-36.6%, vs. 12.3%, 95% CI 4.8%-23.6%） was greater than that for docexatel patients （12 months： 37.3%, 95% CI 26.5%- 48.0%, vs. 23.3%, 95% CI 14.4-33.4）. The progression- free survival without common toxicity criteria grade 3/4 toxicity （PFS-WT） was also statistically significantly longer for patients treated with pemetrexed than patients treated with docetaxel （1.9 months vs. 1.1 months, P=0.002）. Conclusions Chinese patients with nonsquamous NSCLC disease treated with pemetrexed had improved SWT beyond 6 months than those receiving docetaxel. This analysis supports a benefit-to-risk profile that favors pemetrexed over docetaxel in the second-line treatment of Chinese nonsquamous NSCLC patients.
